Publications by authors named "Anne Boisnard"
Disease relapse remains the first cause of mortality of hematological malignancies after allogeneic hematopoietic stem cell transplantation (allo-HCT) for acute myeloid and lymphoid leukemia (AML and ALL) and for myelodysplastic syndroms (MDS). More and more patients are eligible for allo-HCT over the years and for many of them, only reduced intensity conditioning is possible, which is associated with a higher risk of relapse. Knowledge and biotechnology allow us to better identify diseases at very high risk of relapse and to measure residual disease before allo-HCT.
View Article and Find Full Text PDFArticle Synopsis
- The French health authorities established guidelines for "good transfusion practices," but there is limited guidance for managing transfusions in patients who have undergone allogeneic hematopoietic stem transplantation (allo-HCT).
- A workshop aimed to standardize transfusion practices for this patient group where recommendations are lacking.
- Key recommendations include conducting extended blood cell phenotyping before transplantation, monitoring antibody levels, and assessing chimerism at specific intervals post-transplant to adjust transfusion strategies as needed.